Zealand: Deserves a closer lookBUY, Fair Value DKK125 vs. Under Review (+28%)
So far Zealand was seen as Sanofi’s partner for lixisenatide and considering the slow start of Lyxumia and delays in developing LixiLan it did not attract much attention. In addition, the rest of the pipeline was early-stage and was also lacking evidence of potential breakthrough innovation. But Zealand is changing and at least ongoing changes deserve a closer look as the downside appears limited whereas the upside can be huge.
For more information, plaese contact firstname.lastname@example.org